This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

BIO-Europe
Europe's premier partnering event
November 4–6, 2024 | Stockholm, SwedenNovember 12–13, 2024 | Digital Partnering

Laura Koivusalo
CEO and Founder at StemSight
Presenter

Profile

StemSight aims to cure blindness with off-the-shelf regenerative cell therapies based on hypo-immune, allogeneic induced pluripotent stem cells (iPSCs) and degradable biomaterial carriers.
StemSight's lead product, STE-101, is a high-purity limbal stem cell preparation used to restore the stem cell function and the corneal epithelium in patients with limbal stem cell deficiency (LSCD), a rare disease with a significant unmet need.

Agenda Sessions

  • “Take a Chance on Me” Startup spotlight pitch competition

    15:00